Literature DB >> 28990998

Intermediate-Term and Long-Term Outcomes With the Boston Type 1 Keratoprosthesis in Aniridia.

Kevin J Shah1,2, Albert Y Cheung1, Edward J Holland1.   

Abstract

PURPOSE: To report the intermediate- and long-term visual outcomes and complications with the Boston type 1 keratoprosthesis (KPro) for the management of aniridic keratopathy.
METHODS: A retrospective chart review of 46 eyes of 34 patients (20 females and 14 males) with aniridic keratopathy who underwent Boston type 1 KPro surgery by a single surgeon from 2004 to 2012 with minimum 2-year follow-up was conducted. Preoperative, intraoperative, and postoperative parameters were collected and analyzed. The primary outcome was the change in best-corrected visual acuity. Secondary outcomes included the rate of retroprosthetic membrane formation, glaucoma progression, glaucoma tube revisions, and KPro retention.
RESULTS: Mean age of the patients was 43.5 ± 19.8 years with a mean follow-up period of 4.5 ± 1.6 years (range 2-7.4 years). Thirty-four eyes (74%) had previously failed keratoplasty. Thirty-five eyes (76%) previously underwent ocular surface stem cell transplantation, specifically a keratolimbal allograft. Within the first 6 months postoperatively, 74% (34/46) of patients experienced a gain of ≥2 lines of vision. Overall, there was a gain of ≥2 lines of vision in 43.5% (20/46) of patients at last follow-up. The rate of retroprosthetic membrane formation was 61%, the rate of glaucoma onset/progression was 26%, the rate of tube revision was 31%, and the KPro retention rate was 87%.
CONCLUSIONS: This study confirms that initial visual improvement in aniridic keratopathy cases occurs at a high rate with the Boston type 1 KPro but also found progressive loss of these initial visual improvements.

Entities:  

Mesh:

Year:  2018        PMID: 28990998     DOI: 10.1097/ICO.0000000000001412

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  7 in total

1.  Management of Congenital Aniridia-Associated Keratopathy: Long-Term Outcomes from a Tertiary Referral Center.

Authors:  Ghasem Yazdanpanah; Kelley J Bohm; Omar M Hassan; Faris I Karas; Abdelrahman M Elhusseiny; Manachai Nonpassopon; Muanploy Niparugs; Elmer Y Tu; Joel Sugar; Mark I Rosenblatt; Maria S Cortina; Ali R Djalilian
Journal:  Am J Ophthalmol       Date:  2019-11-12       Impact factor: 5.258

Review 2.  The treatment of end-stage corneal disease: penetrating keratoplasty compared with Boston type 1 keratoprosthesis.

Authors:  Steven Bonneau; C Maya Tong; Yelin Yang; Mona Harissi-Dagher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-06       Impact factor: 3.535

Review 3.  Boston Type 1 Keratoprosthesis: Updated Perspectives.

Authors:  Manachai Nonpassopon; Muanploy Niparugs; Maria Soledad Cortina
Journal:  Clin Ophthalmol       Date:  2020-04-29

4.  Commentary: Long-Term Anatomical and Functional Survival of Boston Type 1 Keratoprosthesis in Congenital Aniridia.

Authors:  Yelin Yang; C Maya Tong; Andrea Dahoud; Mona Harissi-Dagher
Journal:  Front Med (Lausanne)       Date:  2021-12-23

5.  Long-Term Anatomical and Functional Survival of Boston Type 1 Keratoprosthesis in Congenital Aniridia.

Authors:  Ariann Dyer; Alix De Faria; Gemma Julio; Juan Álvarez de Toledo; Rafael I Barraquer; Maria Fideliz de la Paz
Journal:  Front Med (Lausanne)       Date:  2021-09-30

6.  Outcomes of Human Leukocyte Antigen-Matched Allogeneic Cultivated Limbal Epithelial Transplantation in Aniridia-Associated Keratopathy-A Single-Center Retrospective Analysis.

Authors:  Joséphine Behaegel; Marie-José Tassignon; Neil Lagali; Alejandra Consejo; Carina Koppen; Sorcha Ní Dhubhghaill
Journal:  Cornea       Date:  2022-01-01       Impact factor: 3.152

Review 7.  Clinical and molecular aspects of congenital aniridia - A review of current concepts.

Authors:  Shailja Tibrewal; Ria Ratna; Abha Gour; Sumita Agarkar; Suneeta Dubey; Suma Ganesh; Ramesh Kekunnaya; Virender Sangwan; Yutao Liu; Vanita Vanita
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.